title: Citalopram for the treatment of adolescent anxiety disorders: a pilot study.
abstract: Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed. Patients were retrospectively assessed using the Clinical Global Impression (CGI)-Severity scale at the beginning and end of treatment. Eighty-two percent (14/17) of patients were rated as much or very much improved on the CGI-Improvement scale after treatment with citalopram. Patients were treated for an average of 156-/+85.1 days at a mean dose of 32.3-/+18.5 mg/day of citalopram. Fifty-three percent (9/17) of this sample had previous exposure to alternative selective serotonin reuptake inhibitors, and 89% (8/9) of those patients responded positively to citalopram. Citalopram appeared well tolerated, with only one patient discontinuing treatment due to side effects. In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents.
authors.affiliation: Department of Child Psychiatry, Harvard Medical School, Boston, Mass, USA. Jprince@partners.org
authors.forename: Jefferson B
authors.initials: JB
authors.lastname: Prince
authors.forename: Jeff Q
authors.initials: JQ
authors.lastname: Bostic
authors.forename: Michael
authors.initials: M
authors.lastname: Monuteaux
authors.forename: Kenneth
authors.initials: K
authors.lastname: Brown
authors.forename: Suzanne
authors.initials: S
authors.lastname: Place
mesh_terms: D000293:Adolescent; D001008:Anxiety Disorders / Q000188:drug therapy; D015283:Citalopram / Q000627:therapeutic use; D006801:Humans; D010865:Pilot Projects; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors